SureNano Science Ltd
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$6.1M
-0.01
SureNano Science Ltd. engages in the sale and distribution of the SureNano surfactant, which is a ready-to-mix food grade compound that provides the base for nano-emulsions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-21. The principal business of the Company is the sale and distribution of the SureNano surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nano-emulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity and taste. The firm has licenses to distribute the SureNano surfactant within Canada, the State of Oklahoma, the United States, and the State of Colorado, United States. SureNano includes Free Flavor technology designed specifically to reduce the naturally bitter notes of many cannabinoids included Cannabidiol (CBD) and tetrahydrocannabinol (THC). The company is also developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery.
SureNano Science Ltd. engages in the sale and distribution of the SureNano surfactant, which is a ready-to-mix food grade compound that provides the base for nano-emulsions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-21. The principal business of the Company is the sale and distribution of the SureNano surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nano-emulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity and taste. The firm has licenses to distribute the SureNano surfactant within Canada, the State of Oklahoma, the United States, and the State of Colorado, United States. SureNano includes Free Flavor technology designed specifically to reduce the naturally bitter notes of many cannabinoids included Cannabidiol (CBD) and tetrahydrocannabinol (THC). The company is also developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.